Blood fat tests to estimate heart and kidney risk in heart and kidney patients
Studies blood fat markers to estimate heart and kidney risk in adults with heart disease.
Plain-language title generated from the registry record
Registry title: Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on Metabolomics
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with coronary heart disease confirmed by coronary angiography and with chronic kidney disease or known kidney function status.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Coronary heart disease confirmed during a hospital stay by coronary angiography: heart attack with ST elevation (STEMI), acute coronary syndrome without ST elevation, or stable angina. Kidney function status must be clear. Chronic kidney disease means eGFR below 60 ml/min/1.73 m² or urine albumin-to-creatinine ratio of 30 mg/g or more, lasting over 3 months.
- Earlier treatment
- People who had a kidney transplant or long-term dialysis cannot join. People who had dialysis for acute kidney failure within 12 weeks before screening cannot join.
- Biomarker or test result
- Kidney tests: eGFR below 60 ml/min/1.73 m², or eGFR of 60 or more with a urine albumin-to-creatinine ratio (uACR) of 30 mg/g or more.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Severe valve disease or severe mechanical complications needing surgery
- Kidney transplant or long-term dialysis
- Severe liver disease (Child-Pugh class C)
- Life expectancy less than 1 year
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06383208, who can take part
Where in China
- China-Japan Friendship HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China-Japan Friendship Hospital
- Trial code
- NCT06383208
- Record updated
- 25 April 2024
- Original description
Coronary heart disease (CHD) combined with chronic kidney disease (CKD) affects a substantial portion of the population and carries a significant disease burden, often leading to poor outcomes. Despite efforts to strictly control traditional risk factors, the efficacy in improving outcomes for patients with both CHD and CKD has been limited. Recent advancements in lipid metabolism research have identified new lipid metabolites associated with the occurrence and prognosis of CHD and CKD. Our preliminary trial has shown that levels of certain lipid metabolites, such as Cer(18:1/16:0), HexCer(18:1/16:0), and PI(18:0/18:1), are notably elevated in patients with CHD and reduced kidney function compared to those with relatively normal kidney function. This suggests that dysregulation of these non-traditional lipid metabolites may contribute to residual risk for adverse outcomes in these patients.Read full original descriptionShow less
Cardiovascular-Renal Adverse oUtcome rIsk aSsessment systEm for Coronary Heart Disease Complicated With Chronic Kidney Disease Based on Targeted Lipid METabolomics
Coronary heart disease (CHD) combined with chronic kidney disease (CKD) affects a substantial portion of the population and carries a significant disease burden, often leading to poor outcomes. Despite efforts to strictly control traditional risk factors, the efficacy in improving outcomes for patients with both CHD and CKD has been limited. Recent advancements in lipid metabolism research have identified new lipid metabolites associated with the occurrence and prognosis of CHD and CKD. Our preliminary trial has shown that levels of certain lipid metabolites, such as Cer(18:1/16:0), HexCer(18:1/16:0), and PI(18:0/18:1), are notably elevated in patients with CHD and reduced kidney function compared to those with relatively normal kidney function. This suggests that dysregulation of these non-traditional lipid metabolites may contribute to residual risk for adverse outcomes in these patients.
Furthermore, the emerging concept of "cardiovascular-kidney-metabolic syndrome" and the availability of new treatment options highlight the urgent need for a risk stratification tool tailored to modern management strategies and treatment goals to guide preventive measures effectively. To address this, we propose to conduct a prospective cohort study focusing on CHD combined with CKD. This study aims to comprehensively understand the clinical characteristics, diagnosis, treatment status, and cardiovascular-kidney prognosis in these patients. Through advanced metabolomics analysis, we seek to identify lipid metabolism profiles and non-traditional lipid metabolites associated with the progression of coronary artery disease in CHD-CKD patients. Leveraging clinical databases and metabolomics data, we will develop a robust risk prediction model for adverse cardiovascular-kidney outcomes, providing valuable guidance for clinical diagnosis, treatment decisions, and ultimately improving patient prognosis.
Inclusion: Age 18-80 years old; Diagnosed with CHD during hospitalization through coronary angiography, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation acute coronary syndrome (NST-ACS), stable angina pectoris; Patients with clarified renal function status; CKD is defined as meeting one of the following criteria, with a duration of more than 3 months: eGFR < 60 ml/min/1.73 m² or eGFR ≥ 60 ml/min/1.73 m² and urinary albumin-to-creatinine ratio (uACR) ≥ 30 mg/g.
Exclusion: Having undergone kidney transplantation or long-term maintenance dialysis; Received acute renal failure dialysis treatment within 12 weeks prior to screening for enrollment; Severe valve disease or severe mechanical complications requiring surgical intervention; Severe psychiatric illness or other reasons that impede follow-up compliance; Severe hematologic disorders or end-stage malignant tumors; Severe liver disease (Child-Pugh class C); Severe chronic lung disease requiring long-term mechanical ventilation support or awaiting lung transplantation; Pregnancy or lactation; Life expectancy less than 1 year.